English
español
Please use this identifier to cite or link to this item:
http://hdl.handle.net/10261/216350
Share/Impact:
Statistics |
![]() ![]() ![]() |
|
|
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |||
|
Title: | The role of ACKR3 in breast, lung, and brain cancer |
Authors: | Neves, María; Fumagalli, Amos; Van den Bor, Jelle; Marin, Philippe; Smit, Martine J.; Mayor Méndez, Federico Jr. |
Issue Date: | 30-Jan-2019 |
Publisher: | American Society for Pharmacology and Experimental Therapeutics |
Citation: | Molecular Pharmacology 96: 819- 825 (2019) |
Abstract: | Recent reports regarding the significance of chemokine receptors in disease have put a spotlight on atypical chemokine receptor 3 (ACKR3). This atypical chemokine receptor is overexpressed in numerous cancer types and has been involved in the modulation of tumor cell proliferation and migration, tumor angiogenesis, or resistance to drugs, thus contributing to cancer progression and metastasis occurrence. Here, we focus on the clinical significance and potential mechanisms underlying the pathologic role of ACKR3 in breast, lung, and brain cancer and discuss its possible relevance as a prognostic factor and potential therapeutic target in these contexts. |
Publisher version (URL): | http://dx.doi.org/10.1124/mol.118.115279 |
URI: | http://hdl.handle.net/10261/216350 |
DOI: | http://dx.doi.org/10.1124/mol.118.115279 |
Identifiers: | doi: 10.1124/mol.118.115279 issn: 1521-0111 |
Appears in Collections: | (CBM) Artículos |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
MayorJrF_TheRoleofACKR3.pdf | 482,5 kB | Adobe PDF | ![]() View/Open |
Show full item record
Review this work
Review this work
WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.